market share

Biotech stocks have climbed steadily higher over the past few weeks. Still, the iShares Nasdaq Biotechnology ETF (IBB) has remained range bound between $240 and $290 for much of 2016.

So with major stock indices hitting new record highs, can biotech stocks break free? Perhaps, says Michael Yee, the industry analyst for RBC Capital Markets. But first, the market wants the political rhetoric surrounding drug prices to calm down, new positive clinical data and, finally, M&A activity.

Weve said a HC rotation from well owned and big outperforming defensive lower risk yield stocks like med tech should eventually shift a bit into underperforming biotech but generalists feel no rush to do that and think we need visibility on an election and whether the political rhetoric on drug pricing will calm down after the general election is won. As PMs position for 2017, defensive outperformers in 2016 may not be the big winners from a risk/reward standpoint vs underperformers like biotech as we enter and think about 2017 so a rotation is possible.

market share: Herman Miller, Inc.(MLHR)

Advisors’ Opinion:

  • [By Monica Gerson]

    Herman Miller, Inc. (NASDAQ: MLHR) is projected to post its quarterly earnings at $0.39 per share on revenue of $544.40 million. International, Ltd. (ADR) (NASDAQ: CTRP) is estimated to post a quarterly loss at $0.09 per share on revenue of $2.81 billion.

market share: Inogen, Inc(INGN)

Advisors’ Opinion:

  • [By Michael A. Robinson]

    I put these rules in action for you in March 2015 when I recommendedInogen Inc.(Nasdaq: INGN)here in these pages.

    Inogen is pioneering the use of portable oxygen concentrators (POCs). And theGoleta, Calif.-based firm boasts breakthrough technology that has disrupted its entire sector.

market share: Valeant Pharmaceuticals International Inc(VRX)

Advisors’ Opinion:

  • [By Ben Levisohn]

    It was a big day for specialty pharmaceutical companies. We dug into Valeant Pharmaceutical International’s (VRX) 25% surge following its guidance and thebeginning of its asset sales, and Endo International’s (ENDP) 22% rise following its own earnings.

  • [By Ben Levisohn]

    It’s official: Valeant Pharmaceuticals International (VRX) plunged 51.5% to $33.51 today, its lowest close since Jan. 5, 2011. To put that in perspective, the company is now valued at $11.4 billion, down from $23.6 billion yesterday. Ouch.

    Ryan Remiorz/The Canadian Press via Associated Press

    Citigroup credit analysts Murali Ganti and team write that Valeant’s “dismal outlook leaves investors stunned” but they aren’t worried about a default just yet–and even maintained their Buy rating on some of the company’s debt (which also got whacked today):


    Valeant Pharmaceuticals International, Inc. reported its long-awaited 4Q 2015 results this morning and while investors were bracing for generally softer results, most were caught off guard. Results came in significantly below expectations, coupled with a forward outlook that painted an even bleaker picture…

    Y 2016 guidance came in significantly below expectations as the company took its outlook lower than what it had previously alluded to, blaming weakness in its Dermatology, Gastrointestinal (GI) and Womens Health units, along with slow starts in Western Europe as well as weakness in its Ophthalmology Rx, Solta and Obagi businesses. The company also revised its FY 2016 Adjusted EBITDA estimates down sharply, reflecting weaker top-line and higher expenses partly related to higher SG&A, new managed care contracts and increased investment in reporting and compliance functions…

    Management will be seeking an amendment with its bank lenders next week to extend the deadline for filing its FY 2015 10-K and its 1Q 2016 10-Q in order to waive any cross default provisions related to its breach of reporting covenant. The companys annual 10-K statement comes due on 03/16/16 for bondholders and 03/30/16 for bank lenders. An event of default will occur if the 10-K is not delivered by 04/29/16 to bank lenders or 05/15/16 to bon

  • [By Ben Levisohn]

    Citigroup bond analystMurali Ganti and team consider the impact of the changes announced by Valeant Pharmaceuticals International (VRX) this morning:

  • [By Monica Gerson]

    Valeant Pharmaceuticals Intl Inc (NYSE: VRX) is estimated to report its quarterly earnings at $2.61 per share on revenue of $2.75 billion.

    FactSet Research Systems Inc. (NYSE: FDS) is expected to report its quarterly earnings at $1.52 per share on revenue of $282.99 million.

  • [By Ben Levisohn]

    Citigroup bond analyst Murali Ganti and team consider the impact of Valeant Pharmaceuticals’ (VRX) statement regarding its attempt to modify its bond covenants…

  • [By Ben Levisohn]

    Deutsche Bank’sGregg Gilbert andGreg Fraser cut their price target on Valeant Pharmaceuticals International (VRX) to $24 from $29, but say they “like the set-up for the stock in the short-term.” They explain why:

market share: Monotype Imaging Holdings Inc.(TYPE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Monotype Imaging Holdings Inc. (NASDAQ: TYPE) was down, falling around 20 percent to $19.86 as the company reported the intent to buy Olapic for around $130 million.